Edition:
United States

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

96.50CHF
3:51am EST
Change (% chg)

CHF-1.65 (-1.68%)
Prev Close
CHF98.15
Open
CHF97.90
Day's High
CHF97.90
Day's Low
CHF96.50
Volume
1,491
Avg. Vol
19,920
52-wk High
CHF150.00
52-wk Low
CHF84.05

Select another date:

Fri, Dec 21 2018

BRIEF-Cosmo Pharmaceuticals: Regulatory Update For Methylene Blue MMX

* NOW IN PROCESS OF FILING A NEW APPEAL TO OFFICE OF NEW DRUGS (OND), CENTER FOR DRUG EVALUATION AND RESEARCH (CDER) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Launches Offering Of Senior Unsecured Convertible Bonds Due 2023

* LAUNCH OF OFFERING OF SENIOR UNSECURED CONVERTIBLE BONDS DUE 2023

BRIEF-Cosmo Pharmaceuticals: FDA Grants Approval For Aemcolo (Tm) (Rifamycin)

* FDA GRANTS APPROVAL FOR AEMCOLO (TM) (RIFAMYCIN), THE FIRST APPROVED ANTIBIOTIC TO TREAT TRAVELER'S DIARRHEA FOR TEN YEARS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cassiopea Enters Into Loan Agreement With Cosmo Pharmaceuticals

* COSMO PHARMACEUTICALS HAS OFFERED AN UNSECURED CREDIT LINE OF EUR 10 MILLION THAT CAN BE INCREASED TO EUR 20 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Updates On Type A Meeting Outcome For MB MMX

* METHYLENE BLUE MMX REGULATORY UPDATE: TYPE A MEETING OUTCOME

BRIEF-Cosmo Pharmaceuticals H1 Revenue Up 15.2 Pct To EUR 36.7 Million

* H1 REVENUE UP 15.2% TO EUR36.7M DRIVEN BY UP-FRONT LICENSE FEESÂ

Select another date: